Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene therapy reverses effects of lethal childhood muscle disorder in mice

01.03.2010
Reversing a protein deficiency through gene therapy can correct motor function, restore nerve signals and improve survival in mice that serve as a model for the lethal childhood disorder spinal muscular atrophy, new research shows.

This muscle-wasting disease results when a child’s motor neurons – nerve cells that send signals from the spinal cord to muscles – produce insufficient amounts of what is called survival motor neuron protein, or SMN. This reduced protein in motor neurons specifically – rather than in other cells throughout the body that contain the protein – is caused by the absence of a single gene.

The researchers used an altered virus to deliver a portion of DNA that makes the SMN protein into the veins of newborn mice ranging in age from 1 to 10 days old. The SMN-laced viral vector injected into the youngest mice reached almost half of their motor neurons, resulting in improved muscle coordination, properly working electrical signals to the muscles and longer survival than in untreated mice, scientists said.

“We’re replacing what we know is lost. And we have shown that when you put the protein in postnatally, it will rescue the genetic defect,” said Arthur Burghes, professor of molecular and cellular biochemistry at Ohio State University and a senior co-author of the study. “This technique corrects the mice considerably more than any drug cocktails being studied as a potential treatment in humans.”

Spinal muscular atrophy (SMA) is a genetic disorder that strikes about one in every 6,000 babies born in the United States, and leads to death in some affected children before age 2. According to the National Institutes of Health, there are many types of SMA, and life expectancy depends on how the disease affects breathing. There is no cure, but medicines and physical therapy help treat symptoms.

The research is published online in the journal Nature Biotechnology.

The scientists used a special form of a virus to deliver the SMN protein to nerve cells in the mice. This virus still has the capability to infect cells but has been altered so it will not copy itself and cause illness in humans, said Brian Kaspar, an investigator in the Research Institute at Nationwide Children’s Hospital and assistant professor of pediatrics at Ohio State, also a senior co-author of the study.

Kaspar’s lab previously determined that this particular viral vector can cross the blood-brain barrier, a characteristic that is required to ensure this protein reaches nerve cells in the spinal cord.

The research group demonstrated that effect in this study, as well, by intravenously injecting some of the disease-model mice with a green fluorescent protein that functioned as a marker of where the virus traveled in the body. Ten days after the injection, 42 percent of spinal motor neurons in these mice showed that they contained the fluorescent protein.

Similarly, mice with spinal muscular atrophy that received the SMN protein via the viral vector when they were 1 day old showed increases of the protein in the brain, spinal cord and muscles within 10 days, though the levels remained lower than the levels of SMN in normal mice.

Those higher levels of the protein appeared to be sufficient to reverse effects of the disease, Burghes said. That is significant because, based on mouse data, the disease is believed to affect people with SMN levels below about 20 percent of normal. But people with only 50 percent of the expected amount of the protein in their motor neurons do not have the disorder.

In addition, a single gene therapy treatment appears to reverse the disease, as opposed to drug treatments under investigation that might elevate SMN protein levels but would require a lifetime of taking medication.

In this study, the researchers tested mice with SMA after the treatment with the protein for their ability to roll themselves upright and for the presence of electrical signals from nerve cells to muscles.

Within 13 days after the injection, 90 percent of the treated mice had the muscle coordination needed to right themselves as quickly as normal animals. By this time, untreated SMA mice already were suffering symptoms that left them unable to right themselves. The day-1 treated mice also were nearly identical to normal mice in their ability to run on a wheel.

In the case of restored nerve impulses, 90 days after the gene therapy, there was no difference in nerve pulses between the treated SMA mice and normal mice, which indicated that the nerves to muscle developed correctly.

The treated SMA mice also gained weight and lived substantially longer than untreated mice with the disease, and some mice were still alive when the paper was submitted 250 days after they received the treatment, Kaspar said.

Improvements this dramatic were seen only in the mice that received SMN on their first two days of life. Later delivery reduced the impact of correction.

“We don’t yet know the exact window of when it is capable of getting into the right cells in a human. Is it a month after birth, or a week after birth? That’s still a question,” Kaspar said.

Complicating this issue is the fact that symptoms of spinal muscular atrophy aren’t typically apparent in infants, and the only existing newborn screening technique has not been implemented because it is considered prohibitively expensive.

“So if you have a technique that needs to be delivered early, then you need a newborn screening,” Burghes noted.

The researchers hope to progress to human clinical trials of this gene therapy technique as soon as the requisite toxicology experiments are in place and federal regulators will allow. This study should help move the process along because of its inclusion of a single viral vector treatment of a 1-day-old macaque with the green fluorescent protein. The experiment showed that the treatment crossed the blood-brain barrier in this species as well, and penetrated motor neurons.

This work is supported by the Miracle for Madison Fund and the National Institute of Neurological Disorders and Stroke (NINDS). Among the NINDS grants is a so-called “GO Grant” on which Burghes is principal investigator. The GO – or Grand Opportunity – grant program was created with American Recovery & Reinvestment Act funds to support work that has potential to lay the foundation for new fields of investigation. Kaspar is the principal investigator on another specialized NINDS grant for Exploratory/Developmental Projects in Translational Research. This program supports projects intended to discover potential targets for therapeutic intervention, to identify candidate therapeutics, or to develop assays, animal models, devices or technologies for screening or developing therapeutics.

Additional co-authors of the study are Kevin Foust, Lyndsey Braun, Adam Bevan and Amanda Haidet of the Center for Gene Therapy in the Research Institute at Nationwide Children’s Hospital; Xueyong Wang and Mark Rich of Wright State University; Vicki McGovern and Thanh Le of Ohio State’s Department of Molecular and Cellular Biochemistry; and Pablo Morales of the Mannheimer Foundation Inc. in Homestead, Fla.

Contacts: Arthur Burghes, (614) 688-4759; burghes.1@osu.edu or Brian Kaspar, (614) 722-5085; Brian.Kaspar@NationwideChildrens.org

Written by Emily Caldwell, (614) 292-8310; caldwell.151@osu.edu

Arthur Burghes | EurekAlert!
Further information:
http://www.osu.edu

More articles from Studies and Analyses:

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>